Literature DB >> 8769313

ER beta: identification and characterization of a novel human estrogen receptor.

S Mosselman1, J Polman, R Dijkema.   

Abstract

A novel estrogen receptor (hereinafter referred to as ER beta) was cloned using degenerate PCR primers. A comparison of the amino acid sequence of ER beta with the "classical' ER (ER alpha) shows a high degree of conservation of the DNA-binding domain (96%), and of the ligand-binding domain (58%). In contrast, the A/B domain, the hinge region and the F-domain are not conserved. Northern blot analysis revealed that ER beta is expressed in human thymus, spleen, ovary and testis. Transient transfections of an ER beta expression construct together with an ERE-based reporter construct in CHO cells clearly demonstrated transactivation of ER beta by 17 beta-estradiol. In addition, the ER alpha antagonist ICI-164384 is a potent antagonist for ER beta as well. Interestingly, the level of transactivation by 17 beta-estradiol is higher for ER alpha than for ER beta, which may reflect suboptimal conditions for ER beta at the level of the ligand, responsive element or cellular context.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8769313     DOI: 10.1016/0014-5793(96)00782-x

Source DB:  PubMed          Journal:  FEBS Lett        ISSN: 0014-5793            Impact factor:   4.124


  371 in total

Review 1.  Estrogen receptor and the SERM concept.

Authors:  G G Kuiper; G J van den Bemd; J P van Leeuwen
Journal:  J Endocrinol Invest       Date:  1999-09       Impact factor: 4.256

2.  Estrogen receptor (ER) modulators each induce distinct conformational changes in ER alpha and ER beta.

Authors:  L A Paige; D J Christensen; H Grøn; J D Norris; E B Gottlin; K M Padilla; C Y Chang; L M Ballas; P T Hamilton; D P McDonnell; D M Fowlkes
Journal:  Proc Natl Acad Sci U S A       Date:  1999-03-30       Impact factor: 11.205

3.  Dominant activity of activation function 1 (AF-1) and differential stoichiometric requirements for AF-1 and -2 in the estrogen receptor alpha-beta heterodimeric complex.

Authors:  G B Tremblay; A Tremblay; F Labrie; V Giguère
Journal:  Mol Cell Biol       Date:  1999-03       Impact factor: 4.272

4.  Distinct expression patterns of ER alpha and ER beta in normal human mammary gland.

Authors:  V Speirs; G P Skliris; S E Burdall; P J Carder
Journal:  J Clin Pathol       Date:  2002-05       Impact factor: 3.411

5.  ER beta inhibits proliferation and invasion of breast cancer cells.

Authors:  G Lazennec; D Bresson; A Lucas; C Chauveau; F Vignon
Journal:  Endocrinology       Date:  2001-09       Impact factor: 4.736

6.  AKT-independent protection of prostate cancer cells from apoptosis mediated through complex formation between the androgen receptor and FKHR.

Authors:  Pengfei Li; Heehyoung Lee; Shaodong Guo; Terry G Unterman; Guido Jenster; Wenlong Bai
Journal:  Mol Cell Biol       Date:  2003-01       Impact factor: 4.272

Review 7.  Of mice and rats: key species variations in the sexual differentiation of brain and behavior.

Authors:  P J Bonthuis; K H Cox; B T Searcy; P Kumar; S Tobet; E F Rissman
Journal:  Front Neuroendocrinol       Date:  2010-05-10       Impact factor: 8.606

8.  Flexible small molecular anti-estrogens with N,N-dialkylated-2,5-diethoxy-4-morpholinoaniline scaffold targets multiple estrogen receptor conformations.

Authors:  Bethany K Asare; Emmanuel Yawson; Rajendram V Rajnarayanan
Journal:  Cell Cycle       Date:  2017-07-19       Impact factor: 4.534

Review 9.  Structural and functional characteristics of oestrogen receptor β splice variants: Implications for the ageing brain.

Authors:  C K Kim; A Torcaso; A Asimes; W C J Chung; T R Pak
Journal:  J Neuroendocrinol       Date:  2018-02       Impact factor: 3.627

10.  Estrogen receptor beta modulates permeability transition in brain mitochondria.

Authors:  Suzanne R Burstein; Hyun Jeong Kim; Jasmine A Fels; Liping Qian; Sheng Zhang; Ping Zhou; Anatoly A Starkov; Costantino Iadecola; Giovanni Manfredi
Journal:  Biochim Biophys Acta Bioenerg       Date:  2018-03-14       Impact factor: 3.991

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.